Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Scenesse Approval Buoys Clinuvel As It Fights Retrophin

This article was originally published in PharmAsia News

Executive Summary

The Australian firm Clinuvel sees good prospects for its dermatology product Scenesse, but at the same time is fighting off unwanted acquisition advances from a corporate suitor.

You may also be interested in...

Keeping Track: Pre-Independence Day Fireworks Crackle At US FDA With Burst Of Approvals And Filings

The latest drug development news and highlights from our US FDA Performance Tracker.

European Backing For AstraZeneca’s Olaparib Bolsters Barriers To Pfizer

Europe’s top medicines advisory panel, the CHMP, also recommended for approval Clinuvel’s Scenesse for severe intolerance to sunlight, Pfizer’s new combination menopausal symptom therapy Duavive, and Baxter’s new hemophilia B therapy Rixubis.

Cynata Sets Stage For Global Fujifilm Cell Therapy Deal

Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts